Accuray (NASDAQ:ARAY) Downgraded by Wall Street Zen to Sell

Accuray (NASDAQ:ARAY) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, BTIG Research boosted their price objective on shares of Accuray from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $5.00.

Accuray Price Performance

ARAY opened at $1.52 on Friday. The company has a market capitalization of $171.21 million, a price-to-earnings ratio of -76.00 and a beta of 1.24. The company has a quick ratio of 0.92, a current ratio of 1.64 and a debt-to-equity ratio of 3.35. The firm has a 50-day moving average price of $1.40 and a 200-day moving average price of $1.57. Accuray has a twelve month low of $1.14 and a twelve month high of $2.95.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). The business had revenue of $127.54 million during the quarter, compared to analysts’ expectations of $123.78 million. Accuray had a negative return on equity of 5.79% and a negative net margin of 0.35%. Accuray has set its FY 2026 guidance at EPS. Equities analysts expect that Accuray will post 0.01 EPS for the current year.

Hedge Funds Weigh In On Accuray

Hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. purchased a new position in Accuray in the 4th quarter worth approximately $35,000. Tower Research Capital LLC TRC grew its stake in Accuray by 604.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 35,177 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 30,182 shares in the last quarter. ProShare Advisors LLC grew its stake in Accuray by 50.7% in the 4th quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 9,187 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Accuray in the 4th quarter worth approximately $66,000. Finally, Williams & Novak LLC grew its stake in Accuray by 25.5% in the 2nd quarter. Williams & Novak LLC now owns 68,970 shares of the medical equipment provider’s stock worth $94,000 after buying an additional 14,000 shares in the last quarter. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.